As the recession bites, some companies are making a tidy fortune, at least in sales. Lawyers involved in litigation for staff losing their jobs, management consultants helping restructure an ailing business, fast food outlets as Britain dumps healthy organic produce in favour of a cheaper fill. Even oil companies have managed to avoid a drop in energy prices.
And the same might be true of pharmaceutical companies. Today Germany’s Bayer AG announced Q3 sales up by nearly 12% and the FY outlook looks rosey too.
But it is really no surprise. Drugs companies benefit from a situation where people pay the real cost of economic downturn. Uncertainty in the work place, stress of losing employment, and depression in a difficult bid to find new employment, all contribute to poor national health and boost the use of drugs to calm or cure.
The real cost of recession is only just unfolding. And the longer it goes on (forecasts of a decade are still oft made) the greater the risk that poor health becomes entrenched in our physique and psyche. It could take a decade more to start to repair the mental and physical harm that politicians’ incompetence and pride are causing to resolving the crisis. But as the decision makers are on a nice government pension, someone can look back and say it was “quite an adventure”.